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Contents 24 
The goals of the present study were: (Experiment 1) to examine the basic capability of 25 
canine corpora lutea (CL) to respond to GnRH by assessing expression of gonadotropin 26 
releasing hormone receptor (GnRH-R) in luteal samples collected throughout the luteal 27 
lifespan from non-pregnant dogs, and (Experiment 2) to investigate the effects of pre-28 
pubertal application of the GnRH agonist deslorelin acetate on luteal function following 29 
the first estrus. Mature CL were collected during the mid-luteal phase (days 30-45) from 30 
treated and control bitches. Transcript levels of several factors were determined: 31 
estrogen receptors (ESR1/ERα, ESR2/ERβ), progesterone (P4)-receptor (PGR), 32 
prolactin receptor (PRLR), PGE2-synthase (PTGES) and PGE2 receptors 33 
(PTGER2/EP2, PTGER4/EP4), vascular endothelial growth factor (VEGFA) and VEGF 34 
receptors (VEGFR-1 and -2), cyclooxygenase 2 (COX2/PTGS2), steroidogenic acute 35 
regulatory protein (STAR) and 3β-hydroxysteroid dehydrogenase (3βHSD). 36 
Additionally, levels of Kisspeptin 1 (Kiss1) and its receptor (KISS1-R) were evaluated. 37 
Although generally low, GnRH-R expression was time-dependent and was elevated 38 
during early diestrus, with a significant decrease towards luteal regression. In 39 
deslorelin-treated and control dogs, its expression was either low or frequently below 40 
the detection limit. EP2 and VEGFR-1 were higher in the treated group, which could be 41 
caused by a feedback mechanism after long-term suppression of reproductive activity. 42 
Despite large individual variations, 3βHSD was higher in the deslorelin-treated group. 43 
This, along with unchanged STAR expression, was apparently not mirrored in increased 44 
luteal functionality, because similar P4 levels were detected in both groups. Finally, the 45 
deslorelin-mediated long-term delay of puberty does not have negative carry-over 46 
effects on subsequent ovarian functionality in bitches. 47 
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Introduction 52 
Gonadotropin releasing hormone (GnRH) is a key regulator of sexual maturation and 53 
reproductive function in mammals that may also modulate the activity of diverse 54 
systems in the brain and many peripheral organs (Ramakrishnappa et al. 2005). The 55 
GnRH receptor (GnRH-R), also known as luteinizing hormone-releasing hormone 56 
receptor (LHRHR), is a member of the G protein-coupled receptors family. When 57 
activated by the hypothalamic GnRH, GnRH-R undergoes a conformational change, 58 
stimulates a G-protein and leads to the synthesis and release of follicle-stimulating 59 
hormone (FSH) and luteinizing hormone (LH), which are responsible for the regulation 60 
of ovarian and testicular functions (Sealfon et al. 1997, Stojilkovic and Catt 1995, 61 
Cheung and Wong 2008).  62 
The secretion of GnRH is regulated by Kisspeptin (Kiss1) (Seminara et al. 2003, Funes 63 
et al. 2003). By acting through its G-protein coupled receptor, Kiss1-R, Kiss1 centrally 64 
stimulates pulsatile GnRH release (Seminara et al. 2003, Funes et al. 2003). Kiss1 and 65 
its receptor were also found in human and rat ovarian tissues, as well as in granulosa-66 
lutein cells in vitro (Gaytan et al. 2009, Cejudo Roman et al. 2012). Also the presence 67 
of GnRH-R transcripts was confirmed in ovarian follicles and corpus luteum (CL), e.g., 68 
in mouse (Torrealday et al. 2013) and human (Choi et al. 2006). Thus, functional 69 
interactions between these two systems, i.e., GnRH and Kiss, within the ovary have 70 
been implicated. 71 
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Long-term release GnRH analogs are synthetic compounds that interact and stimulate 72 
GnRH-R. After an initial sudden increase (i.e. flare-up) effect upon binding to the 73 
receptor, the sustained action of GnRH or its agonists (GnRH-a) causes GnRH-R down-74 
regulation. The inhibitory actions of GnRH and/or GnRH-a on gonadal steroidogenesis 75 
involve suppression of gonadotropin receptors or intermediary enzymes involved in 76 
steroidogenic pathways in the ovary, e.g., P450scc enzyme, 3β-hydroxysteroid 77 
dehydrogenase (3βHSD) or aromatase (Khosravi and Leung 2003, Janssens et al. 2000, 78 
Clayton et al. 1979, Sridaran et al. 1999b). In some reports, GnRH-a were suggested to 79 
suppress expression of FSH and LH receptors (Tilly et al. 1992, Guerrero et al. 1993), 80 
and to decrease gonadotropin-induced cAMP levels or the activities of steroidogenic 81 
factors such as steroidogenic acute regulatory (STAR) protein (Sridaran et al. 1999b, 82 
Shinohara et al. 1985). The presence of both GnRH and the GnRH-R in the 83 
extrapituitary tissues implies an autocrine/paracrine role for GnRH and a potential site 84 
of action for GnRH-a (Aguilar-Rojas and Huerta-Reyes 2009).  85 
With regards to the dog, only one GnRH isoform (GnRH-I) and one receptor type have 86 
been identified in reproductive tissues so far, and their spatial and temporal expression 87 
in canine uterus and placenta have been described recently (Schafer-Somi et al. 2015). 88 
Similar to other mammals, also in the dog GnRH by acting centrally modulates both 89 
inhibitory and stimulatory responses affecting ovarian function and regulating cyclicity 90 
(reviewed in (Gobello 2007)). Importantly, however, with respect to canine luteal 91 
function, neither LH nor GnRH seem to be mandatory at the early luteal stage (Onclin 92 
et al. 2000). Instead, prostaglandins (PGs) produced locally, i.e., within the CL, and in 93 
particular PGE2, appear to be the main luteotrophic factors involved in establishment of 94 
luteal function (reviewed in (Kowalewski 2014)). Concerning the luteotrophic effect of 95 
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PGE2, it was found to induce progesterone (P4) output in lutein cells in vitro 96 
(Kowalewski et al. 2013). Similarly, interfering with cyclooxygenase 2 (COX2, 97 
PTGS2) in vivo with its specific inhibitor (firocoxib, Previcox, Merial), decreases 98 
STAR and 3bHSD mRNA and protein expression (Kowalewski et al. 2015).  99 
Despite recent progress in understanding canine luteal physiology in pregnant and non-100 
pregnant cycles (Kowalewski 2014, Kowalewski 2012, Kowalewski et al. 2015), the 101 
mechanisms of suppression and resumption of ovarian activity and, subsequently, luteal 102 
function after short-/long- term inhibition of gonadal activity remains poorly 103 
understood. Therefore, the first aim of the present study was to investigate the presence 104 
of GnRH-R in CL from non-pregnant dogs (days 5, 15, 25, 35, 45 and 65 post-105 
ovulation, p.o.) during the non-pregnant cycle. With this goal, we aimed to establish the 106 
basic capability of canine CL to respond to GnRH. Additionally, the expression of 107 
GnRH-R, Kiss1, Kiss1-R, 3βHSD, PGR, STAR, COX2 (PTGS2), PTGES, EP2 108 
(PTGER2), EP4 (PTGER4) and the VEGF system was investigated at mid-luteal phase 109 
following the first estrus after long-term pre-pubertal GnRH agonist treatment. 110 
 111 
Materials and Methods 112 
Animals, treatments and tissue materials 113 
For Experiment 1, corpora lutea (CL) were collected by routine ovariohysterectomy 114 
(OHE) from sexually mature (2-8 years old), healthy, crossbreed, non-pregnant dogs 115 
throughout diestrus at days: 5 (n=4), 15 (n=5), 25 (n=5), 35 (n=4), 45 (n=3) and 65 116 
(n=3) post ovulation (p.o.), and were used for assessment of GnRH-R gene expression. 117 
Blood plasma P4 concentrations and vaginal cytology were used to determine the cycle 118 
stage. P4 levels of at least 5 ng/ml were considered as the day of ovulation (Concannon 119 
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et al. 1989). For RNA preservation, tissue samples were placed in RNAlater (Ambion 120 
Biotechnology GmbH, Wiesbaden, Germany) for 24 h at +4°C and afterwards they 121 
were stored at -80 °C until total RNA extraction as described previously (Kowalewski 122 
et al. 2006a). For non-radioactive in situ hybridization (ISH) CL were trimmed of 123 
surrounding tissues and fixed in 10% neutral phosphate-buffered formalin for 24 h at 124 
+4°C.  125 
In experiment 2, the effects of pre-pubertal application of the GnRH agonist deslorelin 126 
acetate on canine luteal function following the first estrus were assessed using luteal 127 
samples that originated from the same animals as in a previous study (Kaya et al. 2015). 128 
Briefly, thirteen healthy, caucasian shepherd and kangal crossbreed, pre-pubertal 129 
bitches aged 4.2±0.6 months with a body weight of 9.5±3.4 kg were used. Implants 130 
containing either 9.4 mg (n = 5) or 4.7 mg (n = 4) deslorelin (Suprelorin; Virbac, 131 
France), or placebo (sodium chloride 0.9%; n = 4), were administered subcutaneously in 132 
the inter-scapular region using a single use applicator. The signs of estrus were 133 
monitored once daily by assessing physical (vulvar appearance and swelling, sero-134 
sanguinous vaginal discharge) and sexual behavioral changes, until occurrence of the 135 
first estrus. Vaginal cytology, serum P4 and estradiol-17b (E2) concentrations were 136 
measured every other day. No clinically detectable systemic side effects were observed 137 
in any of the treated bitches. Control, and those animals that showed estrus signs were 138 
subjected to OHE during the mid-luteal phase (days 30-45) and mature corpora lutea 139 
(CL) were collected. The onset of puberty appears quite variable within several small 140 
and large breeds of dogs. While many smaller breeds reach puberty between 6 and 10 141 
months of age, in some larger breed bitches onset of the first estrous cycle is seen at 2 142 
years of age (England et al. 2010, Root Kustritz 2010). Accordingly, as reported 143 
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previously (Kaya et al. 2015), control animals used in our study showed estrus within 144 
61.9 ± 9.7 weeks after placebo treatment. Four (n=4) of the deslorelin-treated bitches 145 
(n=2 in each of the implanted groups) came into estrus during the 82.7±8.9 weeks of 146 
observation. The other treated bitches (n=3 and n=2 in groups treated with 9.4 mg and 147 
4.7 mg Suprelorin, respectively) did not show estrus by the end of the observation 148 
period at 101.5 weeks when the observation period finished. Consequently, samples 149 
from these 4 dogs, which came into estrus, were merged into one group for further 150 
analyses including semi-quantitative PCR. For mRNA-analysis, tissues were excised, 151 
embedded in Tissue-Tek® (Sanova Pharma GmbH, Vienna, Austria) and frozen at -80°C 152 
until further use.  153 
All experimental procedures were reviewed and approved by the respective animal 154 
welfare authorities of either the Justus Liebig University Giessen, Germany (permit no 155 
II 25-3-19c20/15c GI 18/14), or Local Animal Ethics Committee of the Faculty of 156 
Veterinary Medicine, Kafkas University, Turkey (KAÜ-HADYEK; 2010/30 and 157 
2014/016).  158 
 159 
RNA isolation and semi-quantitative RT-PCR 160 
From all samples, total RNA was extracted by using TRIzol®-Reagent (Life 161 
Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. The 162 
RNA concentrations were measured with a NanoDrop 2000C spectrophotometer 163 
(Thermo Scientific, Wilmington, DE, USA). RNA quality was assessed by checking the 164 
RNA integrity numbers (RIN). For elimination of genomic DNA contamination, total 165 
RNA was DNAse-treated with RQ1 RNase-free DNase (Promega, Dübendorf, 166 
Switzerland) according to the manufacturer’s instructions. Reverse transcription of 167 
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isolated RNA was performed in an Eppendorf Mastercycler (Vaudaux-Eppendorf AG, 168 
Basel, Switzerland) using reagents from Applied Biosystems by Thermo Fisher 169 
Scientific (Foster City, CA, USA). Water instead of cDNA and the so-called RT-minus 170 
controls were run as negative controls. Then, semi-quantitative (TaqMan) RT-PCR 171 
analyses were performed in an automated fluorometer ABI PRISM 7500 Sequence 172 
Detection System from Applied Biosystems as previously described, ensuring 173 
approximately 100% efficiency of reactions (Kowalewski et al. 2006a, Kowalewski et 174 
al. 2011a, Kowalewski et al. 2006b). Reaction conditions were as follows: initial 175 
denaturation at 95 °C for 10 min, followed by 40 cycles consisting of 95 °C for 15s and 176 
60 °C for 60s. Three different reference genes (GAPDH, CYCLOPHILIN A and b-177 
ACTIN) were used for normalization and relative expression changes were calculated 178 
using the comparative CT (DDCT) method according to the protocol of the 179 
manufacturer of the ABI Prism 7500. The list of primers and TaqMan probes used in 180 
the semi-quantitative real time PCR are presented in Table 1. In addition, canine-181 
specific TaqMan Gene Expression Assays purchased from Applied Biosystems were 182 
used for CYCLOPHILIN A (Prod. No. Cf03986523_gH), b-ACTIN (Prod. No. 183 
Cf03023880_g1), GnRH-R (Prod. No. Cf02623893_m1), and Kiss1-R (Prod. No. 184 
Cf02715933_u1). 185 
 186 
Hormone analysis 187 
Blood samples were centrifuged for 3 min at 3000 g and the sera obtained were stored 188 
at -18°C until analysis. The concentrations of P4 (ng/ml) and E2 (pg/ml) were measured 189 
in serum samples using the electro-chemiluminescence immunoassay (ECLIA) with a 190 
fully automated Cobas Modular E170 Analyzer (Roche Diagnostics, Mannheim, 191 
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Germany) in an internationally certified commercial laboratory (Düzen Laboratories 192 
Group, Ankara, Turkey) as described before (Agaoglu et al. 2011). Extraction efficiency 193 
was >95%. The mean intra- and inter-assay coefficients of variance for P4 were 3.2 % 194 
and 1.7%, respectively. The analytic sensitivity was 0.03 ng/ml. Values for E2 assay 195 
were 5.0 pg/ml (sensitivity), 3.0% (intra-assay coefficient) and 1.7% (inter-assay 196 
coefficient). 197 
 198 
In situ hybridization (ISH) 199 
A non-radioactive ISH method was carried out to localize GnRH-R mRNA in the canine 200 
CL. Total RNA was extracted and hybridization probes were prepared following the 201 
same method used in our previous studies (Kowalewski et al. 2006a). Briefly, reverse 202 
transcription was performed using the following canine specific primers in order to 203 
prepare (cRNA) probes: GnRH-R forward 5`- CGC CTC TCC TGA ACA GAA TC-3`, 204 
GnRH-R, reverse 5`- GTT GGC CAA GGT CAG ATG TT-3`; the amplicon length was 205 
250 bp. The PCR products were separated on ethidium bromide-stained 2% agarose 206 
gels, then isolated using the Qiaex II gel extraction system (Qiagen GmbH Hilden, 207 
Germany) and subcloned into the pGEM-T vector (Promega, Duebendorf, Switzerland). 208 
Incorporation of selected genes in the pGEM-T vector was proved by control-digestion 209 
with NcoI and NotI restriction enzymes (New England Biolabs, Frankfurt, Germany) 210 
and sent for commercial sequencing (Microsynth, Balgach, Switzerland). Afterwards, 211 
pGEM-T vectors were linearized with the restriction enzymes NcoI and NotI, for 212 
antisense cRNA and sense cRNA, respectively. Hybridization probes were prepared 213 
using the DIG-RNA labelling kit according to the manufacturer’s protocols (Roche 214 
Diagnostics, Mannheim, Germany) Then, cRNA probes were applied to each section 215 
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and incubated overnight at 37°C for hybridization. Afterwards, hybridized probes were 216 
detected with alkaline phosphatase-conjugated, sheep anti-DIG Fab Fragments (Roche 217 
Diagnostics) diluted 1:5000, and signals were visualized using the substrate 5-bromo-4-218 
chloro-3-indolyl phosphate and nitroblue tetrazolium (NBT/BCIP; Roche Diagnostics). 219 
No counterstaining was applied.  220 
 221 
Statistical analysis 222 
GraphPad version 3.06 software (GraphPad Software, Inc., San Diego, California, 223 
USA) was used to assess differences in target gene expression. Statistical analysis was 224 
done using either the Kruskal Wallis test (a nonparametric ANOVA) followed by 225 
Dunn's multiple comparison test to examine the effect of time on GnRH-R expression in 226 
canine CL throughout the luteal life span, or else an unpaired two-tailed Student's t-test 227 
was applied for pairwise comparisons. Values of P<0.05 were considered significant. In 228 
experiments evaluating gene expression following deslorelin treatment, the numerical 229 
data are presented as geometric means with geometric standard deviation (Xg ± SD). 230 
Mean values ± standard deviation (SD) are presented for experiments evaluating GnRH-231 
R expression throughout diestrus. For the analyses of P4 and E2 concentrations, PASW 232 
statistics software (version 17 for Windows, SPSS Ltd, Hong Kong) was used. 233 
Normality and homogeneity of groups were determined by the Shapiro-Wilk test. Due 234 
to the relatively small sample numbers, a non-parametric Mann-Whitney U test was 235 
performed for comparisons between groups (i.e., treated vs. control). Data were 236 
summarized as descriptive statistics, display concentrations of the respective hormone 237 
on the day of tissue sample collection and are shown as box and whisker plots (Fig. 1).  238 
 239 
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Results 240 
Hormonal profiles 241 
No significant differences were observed for P4 and E2 concentrations between treated 242 
and control animals at the time of tissue collection (P>0.05, Fig. 1).  243 
 244 
Localization of canine GnRH-R mRNA and its expression in canine CL 245 
throughout the luteal phase in non-pregnant dogs.  246 
Although generally low, GnRH-R expression was time-dependent in non-pregnant dogs 247 
CL throughout the luteal phase (P<0.0001). The highest expression was detected at the 248 
beginning of the luteal phase, at days 5 and 15 p.o.. This was followed by a significant 249 
decrease towards the late luteal phase (days 5 vs. 65 p.o. P<0.001, and days 15 vs. 65 250 
p.o. P<0.01) (Fig. 2A). 251 
In order to localize GnRH-R-mRNA, non-radioactive ISH was performed during the 252 
early luteal stage when its expression was at the highest relative mRNA levels. Specific 253 
signals were targeted to luteal cells (Fig. 2B). No background staining was observed in 254 
negative controls (sense probes) (Fig. 2C) 255 
 256 
Effects of deslorelin-treatment on luteal gene expression at mid-diestrus 257 
Whereas the expression of STAR did not differ significantly (P=0.09) between the two 258 
groups (i.e. treated versus non-treated), the expression of 3bHSD was higher (P=0.03) 259 
in deslorelin-treated animals (Fig. 3). As for genes encoding for the PG system, the 260 
expression of COX2 (PTGS2) and PTGES was not affected by the treatment (P=0.6 and 261 
P=0.2, respectively). Expression of the two PGE2 receptors was affected in CL of 262 
treated dogs, showing opposite effects: EP2 was significantly higher in treated animals 263 
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(P=0.04), while EP4 expression was lower in that group (P=0.04) (Fig. 3). With regards 264 
to angiogenic factors of the VEGF-family, only the expression of VEGFR1 was affected 265 
significantly (P=0.04) and was elevated in CL of deslorelin-treated animals, whereas 266 
VEGFA and VEGRF2 did not differ (P=0.1 and P=0.6, respectively) (not shown).  267 
Expression of the following genes did not differ between the two groups: Kiss1-R 268 
(P=0.3), PRLR (P=0.2), PGR (P=0.9), ERa (P=0.08) and ERb (P=0.2).  269 
In both deslorelin-treated and control dogs, the relative expression of GnRH-R and 270 
Kiss1 was low and in some samples below the detection limits, preventing us from 271 
performing statistical analysis.  272 
 273 
Discussion 274 
In addition to its well-known properties in regulating the mammalian pituitary gland, 275 
and thereby, reproductive function, the GnRH-system exerts many paracrine, autocrine 276 
and endocrine actions in numerous extrapituitary tissues including cancer cells 277 
(Aguilar-Rojas and Huerta-Reyes 2009), prostate, ovary,  (Cheung and Wong 2008), 278 
placenta (Schafer-Somi et al. 2015, Cheung and Wong 2008, Aguilar-Rojas and Huerta-279 
Reyes 2009) and breast (Cheung and Wong 2008). While the role of this system in 280 
ovarian steroidogenesis (Sridaran et al. 1999a, Sridaran et al. 1999b) and apoptosis 281 
(Papadopoulos et al. 1999, Sridaran et al. 1998, Sridaran et al. 1999b, Sridaran et al. 282 
1999a) has been demonstrated in several mammalian species, there is still a lack of 283 
information regarding its possible functions in the domestic canine species. Therefore, 284 
here, first we attempted to show the basic capability of canine CL to respond directly to 285 
GnRH, by investigating the mRNA expression of its receptor GnRH-R during the non-286 
pregnant cycle (days 5, 15, 25, 35, 45 and 65 post-ovulation).  287 
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Indeed, although generally low, the transcripts encoding for GnRH-R were detectable in 288 
luteal samples throughout the non-pregnant cycle. There was a gradual decrease 289 
towards the mid-luteal phase and further downregulation was seen at the late luteal 290 
stage. A similar expression pattern of GnRH-R was also described for the pregnant rat 291 
ovary, where progression of the luteal phase was associated with diminishing 292 
expression of immunoreactive GnRH-R (Sengupta et al. 2008). As detected by ISH, 293 
GnRH-R mRNA was localized in luteal cells, matching similar expression pattern of 294 
GnRH-R in other mammalian species, e.g., monkey (Chakrabarti et al. 2008) and rabbit 295 
(Zerani et al. 2010). Therefore, our findings imply possible regulatory involvement of 296 
GnRH within the canine CL. This is supported by the presence of detectable amounts of 297 
Kiss1-R in canine CL. The relative importance of locally-expressed GnRH-R for canine 298 
luteal physiology remains, however, to be investigated further.  299 
Hormonal approaches to postpone or prevent the onset of cyclicity in dogs are being 300 
explored. In contrast to its natural pulsatile hypothalamic secretion, continuous 301 
exogenous administration of a GnRH agonist results in down-regulation of the GnRH 302 
receptors and desensitization of the pituitary gonadotrophs (Finch et al. 2009). 303 
Furthermore, suppression of LH and FSH levels and gonadal steroidogenic activity is 304 
observed, thereby blocking reproductive function (Rubion et al. 2006, Trigg et al. 305 
2001). Therefore, in recent years, GnRH-analogs have been developed as a non-surgical 306 
method to control reproduction in dogs, as well as in cats (Kutzler and Wood 2006, 307 
Trigg et al. 2001).  308 
The knowledge about the application of GnRH agonists in females is, however, still not 309 
fully established, mostly due to the “flare-up” effect they may cause on the pituitary-310 
gonadal axis. In a previous study utilizing the same animals (Kaya et al. 2015), the 311 
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effects of deslorelin implants on epiphyseal closure, body development and time to 312 
onset of puberty were investigated. It has been clearly demonstrated that deslorelin 313 
could be used efficiently for delaying puberty in pre-pubertal dogs. Following this line, 314 
in the present study, the possible long-term effects of Suprelorin treatment on canine 315 
luteal function were assessed by investigating the expression of several factors involved 316 
in establishment and maintenance of canine CL following the first estrus after long-term 317 
prepubertal treatment. Accordingly, during the early luteal phase, PGs appear to be 318 
among the most important factors involved in establishment of luteal function in the 319 
dog (Kowalewski et al. 2013). Afterwards, during luteal maintenance, PRL acts as the 320 
main luteotropic factor (Okkens et al. 1990), with its receptor, PRLR, being upregulated 321 
at early- and mid-luteal phase (Kowalewski et al. 2011b). STAR protein is a key factor 322 
regulating the provision of steroidogenic substrates and is one of the main downstream 323 
responders in the steroidogenic cascade, the first enzymatic step of which is catalyzed 324 
by 3bHSD. The expression of both proteins mirrors circulating P4 levels in the dog 325 
(Kowalewski et al. 2006a, Kowalewski and Hoffmann 2008). Furthermore, 326 
establishment of luteal function depends on vascularization, with the VEGF system 327 
being the most prominent representative of the entire family of angiogenic and 328 
vasoactive factors. This led us to investigate the expression levels of all these important 329 
factors in CL from GnRH-treated dogs, enquiring about possible carry-over effects in 330 
the following cycle after the postponed onset of estrus. Whereas COX2 and PTGES 331 
remained unaffected, the expression profiles of EP2 and EP4 receptors were changed 332 
significantly: whereas EP2 was elevated, EP4 expression was lower in the CL of treated 333 
animals. As for EP2, we found increased expression of one of the VEGF receptors, 334 
VEGFR1. Interestingly, in contrast to unaffected STAR mRNA levels, we found 335 
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upregulated levels of 3βHSD in treated animals. However, neither the enhanced 336 
expression of EP2 and VEGFR1 nor the elevated levels of 3bHSD were related to 337 
increased luteal functionality, as similar P4 and E2 plasma levels were detected in both 338 
groups, i.e., control and treated bitches. We interpreted this as a part of a possible 339 
feedback mechanism following suppression of pituitary function prior to ovulation and 340 
development of the luteal structure. The expression of PRLR and steroid hormone 341 
receptors, PGR, ERa and ERb, remained unaffected.  342 
 343 
In conclusion, by showing higher transcript abundance at the beginning of the luteal 344 
phase, the luteal presence of GnRH-R implies possible direct endocrine regulatory 345 
involvement of GnRH within the canine CL. Furthermore, despite an imbalance in the 346 
expression of some important luteotropic regulatory factors, the long-term delay of 347 
puberty by means of GnRH analog deslorelin treatment seems to have no negative 348 
carry-over-effects on subsequent reproductive activity and ovarian functionality in 349 
bitches. Certainly, due to the relatively low numbers of animals used in our study, the 350 
results presented herein are not definitive and future studies involving larger numbers of 351 
dogs should be undertaken. Nevertheless, here, the first insights into the local effects of 352 
GnRH in canine CL have been obtained, and the expression of GnRH-R has been shown 353 
for the first time in the dog CL.  354 
 355 
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Figure Legends 386 
Fig. 1. Distributions of progesterone (P4) and estradiol-17b (E2) concentrations (ng/ml 387 
and pg/ml, respectively) in control and deslorelin-treated bitches on the day of tissue 388 
collection (P>0.05) in Experiment 2.  389 
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 390 
Fig. 2. Expression of GnRH receptor (GnRH-R) (A) and localization of GnRH-R 391 
mRNA in canine CL (B) (Experiment 1). (A) Relative changes in GnRH-R mRNA 392 
expression were determined by real time time (TaqMan) PCR in luteal samples 393 
throughout diestrus in non-pregnant dogs.  Bars with different letters differ 394 
significantly: d5 vs. d65 P<0.001, and d15 vs. d65: P<0.01. d5 - d65 = days after 395 
ovulation. (B) Localization of GnRH-R mRNA as determined by in situ hybridization 396 
(ISH) in canine CL during early diestrus; representative microphotographs from d15 397 
after ovulation are shown. Signals were localized to luteal cells (solid arrowheads). (C) 398 
There is no background staining in negative controls.  399 
 400 
Fig. 3. Expression of selected target gene mRNAs as determined by real time (TaqMan) 401 
PCR in luteal samples collected from deslorelin-treated and control dogs following the 402 
first estrus. Numerical data are presented as geometric means (Xg) ± geometric standard 403 
deviation (SD). 404 
 405 
Table 1. List of primers and TaqMan probes used for the semi-quantitative PCR  406 
 407 
 408 
  409 
 18 
Literature 410 
Agaoglu A. R.; Schafer-Somi S.; Kaya D.; Kucukaslan I.; Emre B.; Gultiken N.; 411 
Mulazimoglu B. S.; Colak A.; Aslan S., 2011: The intravaginal application of 412 
misoprostol improves induction of abortion with aglepristone. Theriogenology, 413 
76 74-82. 414 
Aguilar-Rojas A.; Huerta-Reyes M., 2009: Human gonadotropin-releasing hormone 415 
receptor-activated cellular functions and signaling pathways in extra-pituitary 416 
tissues and cancer cells (Review). Oncol Rep, 22 981-990. 417 
Cejudo Roman A.; Pinto F. M.; Dorta I.; Almeida T. A.; Hernandez M.; Illanes M.; 418 
Tena-Sempere M.; Candenas L., 2012: Analysis of the expression of neurokinin 419 
B, kisspeptin, and their cognate receptors NK3R and KISS1R in the human 420 
female genital tract. Fertil Steril, 97 1213-1219. 421 
Chakrabarti N.; Subbarao T.; Sengupta A.; Xu F.; Stouffer R. L.; Sridaran R., 2008: 422 
Expression of mRNA and proteins for GnRH I and II and their receptors in 423 
primate corpus luteum during menstrual cycle. Mol Reprod Dev, 75 1567-1577. 424 
Cheung L. W.; Wong A. S., 2008: Gonadotropin-releasing hormone: GnRH receptor 425 
signaling in extrapituitary tissues. FEBS J, 275 5479-5495. 426 
Choi J. H.; Gilks C. B.; Auersperg N.; Leung P. C., 2006: Immunolocalization of 427 
gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor 428 
during follicular development in the human ovary. J Clin Endocrinol Metab, 91 429 
4562-4570. 430 
Clayton R. N.; Harwood J. P.; Catt K. J., 1979: Gonadotropin-releasing hormone 431 
analogue binds to luteal cells and inhibits progesterone production. Nature, 282 432 
90-92. 433 
Concannon P. W.; McCann J. P.; Temple M., 1989: Biology and endocrinology of 434 
ovulation, pregnancy and parturition in the dog. J Reprod Fertil Suppl, 39 3-25. 435 
England G. C. W.; Heimendahl A. v.; British Small Animal Veterinary Association., 436 
2010: BSAVA manual of canine and feline reproduction and neonatology. 2nd 437 
edn. British Small Animal Veterinary Association, Quedgeley, Gloucester 438 
England. 439 
Finch A. R.; Caunt C. J.; Armstrong S. P.; McArdle C. A., 2009: Agonist-induced 440 
internalization and downregulation of gonadotropin-releasing hormone 441 
receptors. Am J Physiol Cell Physiol, 297 C591-600. 442 
Funes S.; Hedrick J. A.; Vassileva G.; Markowitz L.; Abbondanzo S.; Golovko A.; 443 
Yang S.; Monsma F. J.; Gustafson E. L., 2003: The KiSS-1 receptor GPR54 is 444 
essential for the development of the murine reproductive system. Biochem 445 
Biophys Res Commun, 312 1357-1363. 446 
Gaytan F.; Gaytan M.; Castellano J. M.; Romero M.; Roa J.; Aparicio B.; Garrido N.; 447 
Sanchez-Criado J. E.; Millar R. P.; Pellicer A.; Fraser H. M.; Tena-Sempere M., 448 
2009: KiSS-1 in the mammalian ovary: distribution of kisspeptin in human and 449 
marmoset and alterations in KiSS-1 mRNA levels in a rat model of ovulatory 450 
dysfunction. Am J Physiol Endocrinol Metab, 296 E520-531. 451 
Gobello C., 2007: New GnRH analogs in canine reproduction. Anim Reprod Sci, 100 1-452 
13. 453 
Guerrero H. E.; Stein P.; Asch R. H.; de Fried E. P.; Tesone M., 1993: Effect of a 454 
gonadotropin-releasing hormone agonist on luteinizing hormone receptors and 455 
steroidogenesis in ovarian cells. Fertil Steril, 59 803-808. 456 
 19 
Janssens R. M.; Brus L.; Cahill D. J.; Huirne J. A.; Schoemaker J.; Lambalk C. B., 457 
2000: Direct ovarian effects and safety aspects of GnRH agonists and 458 
antagonists. Hum Reprod Update, 6 505-518. 459 
Kaya D.; Schafer-Somi S.; Kurt B.; Kuru M.; Kaya S.; Kacar C.; Aksoy O.; Aslan S., 460 
2015: Clinical use of deslorelin implants for the long-term contraception in 461 
prepubertal bitches: effects on epiphyseal closure, body development, and time 462 
to puberty. Theriogenology, 83 1147-1153. 463 
Khosravi S.; Leung P. C., 2003: Differential regulation of gonadotropin-releasing 464 
hormone (GnRH)I and GnRHII messenger ribonucleic acid by gonadal steroids 465 
in human granulosa luteal cells. J Clin Endocrinol Metab, 88 663-672. 466 
Kowalewski M. P., 2012: Endocrine and molecular control of luteal and placental 467 
function in dogs: a review. Reprod Domest Anim, 47 Suppl 6 19-24. 468 
Kowalewski M. P., 2014: Luteal regression vs. prepartum luteolysis: regulatory 469 
mechanisms governing canine corpus luteum function. Reprod Biol, 14 89-102. 470 
Kowalewski M. P.; Fox B.; Gram A.; Boos A.; Reichler I., 2013: Prostaglandin E2 471 
functions as a luteotrophic factor in the dog. Reproduction, 145 213-226. 472 
Kowalewski M. P.; Hoffmann B., 2008: Molecular cloning and expression of StAR 473 
protein in the canine corpus luteum during dioestrus. Exp Clin Endocrinol 474 
Diabetes, 116 158-161. 475 
Kowalewski M. P.; Ihle S.; Siemieniuch M. J.; Gram A.; Boos A.; Zdunczyk S.; 476 
Fingerhut J.; Hoffmann B.; Schuler G.; Jurczak A.; Domoslawska A.; Janowski 477 
T., 2015: Formation of the early canine CL and the role of prostaglandin E2 478 
(PGE2) in regulation of its function: an in vivo approach. Theriogenology, 83 479 
1038-1047. 480 
Kowalewski M. P.; Mason J. I.; Howie A. F.; Morley S. D.; Schuler G.; Hoffmann B., 481 
2006a: Characterization of the canine 3beta-hydroxysteroid dehydrogenase and 482 
its expression in the corpus luteum during diestrus. J Steroid Biochem Mol Biol, 483 
101 254-262. 484 
Kowalewski M. P.; Meyer A.; Hoffmann B.; Aslan S.; Boos A., 2011a: Expression and 485 
functional implications of peroxisome proliferator-activated receptor gamma 486 
(PPARgamma) in canine reproductive tissues during normal pregnancy and 487 
parturition and at antiprogestin induced abortion. Theriogenology, 75 877-886. 488 
Kowalewski M. P.; Michel E.; Gram A.; Boos A.; Guscetti F.; Hoffmann B.; Aslan S.; 489 
Reichler I., 2011b: Luteal and placental function in the bitch: spatio-temporal 490 
changes in prolactin receptor (PRLr) expression at dioestrus, pregnancy and 491 
normal and induced parturition. Reprod Biol Endocrinol, 9 109. 492 
Kowalewski M. P.; Schuler G.; Taubert A.; Engel E.; Hoffmann B., 2006b: Expression 493 
of cyclooxygenase 1 and 2 in the canine corpus luteum during diestrus. 494 
Theriogenology, 66 1423-1430. 495 
Kutzler M.; Wood A., 2006: Non-surgical methods of contraception and sterilization. 496 
Theriogenology, 66 514-525. 497 
Okkens A. C.; Bevers M. M.; Dieleman S. J.; Willemse A. H., 1990: Evidence for 498 
prolactin as the main luteotrophic factor in the cyclic dog. Vet Q, 12 193-201. 499 
Onclin K.; Verstegen J. P.; Concannon P. W., 2000: Time-related changes in canine 500 
luteal regulation: in vivo effects of LH on progesterone and prolactin during 501 
pregnancy. J Reprod Fertil, 118 417-424. 502 
Papadopoulos V.; Dharmarajan A. M.; Li H.; Culty M.; Lemay M.; Sridaran R., 1999: 503 
Mitochondrial peripheral-type benzodiazepine receptor expression. Correlation 504 
 20 
with gonadotropin-releasing hormone (GnRH) agonist-induced apoptosis in the 505 
corpus luteum. Biochem Pharmacol, 58 1389-1393. 506 
Ramakrishnappa N.; Rajamahendran R.; Lin Y. M.; Leung P. C., 2005: GnRH in non-507 
hypothalamic reproductive tissues. Anim Reprod Sci, 88 95-113. 508 
Root Kustritz M. V., 2010: Clinical canine and feline reproduction : evidence-based 509 
answers. Wiley-Blackwell, Ames, Iowa. 510 
Rubion S.; Desmoulins P. O.; Riviere-Godet E.; Kinziger M.; Salavert F.; Rutten F.; 511 
Flochlay-Sigognault A.; Driancourt M. A., 2006: Treatment with a subcutaneous 512 
GnRH agonist containing controlled release device reversibly prevents puberty 513 
in bitches. Theriogenology, 66 1651-1654. 514 
Schafer-Somi S.; Kowalewski M. P.; Kanca H.; Bozkurt M. F.; Gram A.; Sabitzer S.; 515 
Kucukaslan I.; Ay S. S.; Aslan S., 2015: GnRH and its receptor (GnRH-R) are 516 
expressed in the canine placenta and uterus. Theriogenology, 84 1482-1489. 517 
Sealfon S. C.; Weinstein H.; Millar R. P., 1997: Molecular mechanisms of ligand 518 
interaction with the gonadotropin-releasing hormone receptor. Endocr Rev, 18 519 
180-205. 520 
Seminara S. B.; Messager S.; Chatzidaki E. E.; Thresher R. R.; Acierno J. S., Jr.; 521 
Shagoury J. K.; Bo-Abbas Y.; Kuohung W.; Schwinof K. M.; Hendrick A. G.; 522 
Zahn D.; Dixon J.; Kaiser U. B.; Slaugenhaupt S. A.; Gusella J. F.; O'Rahilly S.; 523 
Carlton M. B.; Crowley W. F., Jr.; Aparicio S. A.; Colledge W. H., 2003: The 524 
GPR54 gene as a regulator of puberty. N Engl J Med, 349 1614-1627. 525 
Sengupta A.; Chakrabarti N.; Sridaran R., 2008: Presence of immunoreactive 526 
gonadotropin releasing hormone (GnRH) and its receptor (GnRHR) in rat ovary 527 
during pregnancy. Mol Reprod Dev, 75 1031-1044. 528 
Shinohara O.; Knecht M.; Catt K. J., 1985: Inhibition of gonadotropin-induced 529 
granulosa cell differentiation by activation of protein kinase C. Proc Natl Acad 530 
Sci U S A, 82 8518-8522. 531 
Sridaran R.; Hisheh S.; Dharmarajan A. M., 1998: Induction of apoptosis by a 532 
gonadotropin-releasing hormone agonist during early pregnancy in the rat. 533 
Apoptosis, 3 51-57. 534 
Sridaran R.; Lee M. A.; Haynes L.; Srivastava R. K.; Ghose M.; Sridaran G.; Smith C. 535 
J., 1999a: GnRH action on luteal steroidogenesis during pregnancy. Steroids, 64 536 
618-623. 537 
Sridaran R.; Philip G. H.; Li H.; Culty M.; Liu Z.; Stocco D. M.; Papadopoulos V., 538 
1999b: GnRH agonist treatment decreases progesterone synthesis, luteal 539 
peripheral benzodiazepine receptor mRNA, ligand binding and steroidogenic 540 
acute regulatory protein expression during pregnancy. J Mol Endocrinol, 22 45-541 
54. 542 
Stojilkovic S. S.; Catt K. J., 1995: Expression and signal transduction pathways of 543 
gonadotropin-releasing hormone receptors. Recent Prog Horm Res, 50 161-205. 544 
Tilly J. L.; LaPolt P. S.; Hsueh A. J., 1992: Hormonal regulation of follicle-stimulating 545 
hormone receptor messenger ribonucleic acid levels in cultured rat granulosa 546 
cells. Endocrinology, 130 1296-1302. 547 
Torrealday S.; Lalioti M. D.; Guzeloglu-Kayisli O.; Seli E., 2013: Characterization of 548 
the gonadotropin releasing hormone receptor (GnRHR) expression and activity 549 
in the female mouse ovary. Endocrinology, 154 3877-3887. 550 
Trigg T.; Wright P.; Armour A.; Williamson P.; Junaidi A.; Martin G.; Doyle A.; Walsh 551 
J., 2001: Use of a GnRH analogue implant to produce reversible long-term 552 
 21 
suppression of reproductive function in male and female domestic dogs. J 553 
Reprod Fertil Suppl,  251-261. 554 
Zerani M.; Parillo F.; Brecchia G.; Guelfi G.; Dall'Aglio C.; Lilli L.; Maranesi M.; 555 
Gobbetti A.; Boiti C., 2010: Expression of type I GNRH receptor and in vivo 556 
and in vitro GNRH-I effects in corpora lutea of pseudopregnant rabbits. J 557 
Endocrinol, 207 289-300. 558 
 559 
 560 
Table 1
Gene Primer sequence
Product
length
(bp)
Accession
number
Kiss 1
For: 5’-CCT GGT TTC TTG GCA GCT AAT G -3’ 
Rev: 5’ -GTC TCC ATG GGT GCC ACC TT-3’
TaqMan: 5’ –TCT CCT CTG TGC CAC TTC CTT CAG GGAG-3’
81 KJ512885
GAPDH For: 5’-GCT GCC AAA TAT GAC GAC ATC-3’
Rev: 5’-GTA GCC CAG GAT GCC TTT GAG-3’
TaqMan p: 5’-TCC CTC CGA TGC CTG CTT CAC TAC CTT-3’
75 AB028142
3β-HSD
For: 5-GGGTACTCAGCTCCTGTTGGAA-3ʹ
Rev: 5-GCCACCTCTATGGTGCTGGTAT-3ʹ
TaqMan p: 5-TGCCCAGGCTAGTGTGCCGATCTT-3ʹ
78 AY739720.1
PGR
For: 5’-CGA GTC ATT ACC TCA GAA GAT TTG TTT-3’
Rev: 5’-CTT CCA TTG CCC TTT TAA AGA AGA-3’
TaqMan: 5’-AAG CAT CAG GCT GTC ATT ATG GTG TCC TAA CTT-3’
113 NM_001003074
StAR
For: 5’-CGA GGC TCC ACC TGT GTG T-3’
Rev: 5’-CCT TTC TGC TCA GGC ATC TC-3’
TaqMan: 5’-CTG GCA TGG CCA CAC ATT TC-3’
65 EF522840
COX2
For: 5ʹ-GGA GCA TAA CAG AGT GTG TGA
Rev: TGT G-3ʹ 5ʹ-AAG TAT TAG CCT GCT CGT CTG GAA T-3ʹ
TaqMan: 5ʹ-CGC TCA TCA TCC CAT TCT GGG TGC-3ʹ
87 HQ110882
PTGES
For: 5ʹ-GTC CTG GCG CTG GTG AGT-3ʹ
Rev: 5ʹ-ATG ACA GCC ACC ACG TAC ATC T-3ʹ
TaqMan: 5ʹ-TCC CAG CCT TCC TGC TCT GCA GC-3ʹ
89 NM_001122854
VEGFA
For: 5ʹ-GTG CCC ACT GAG GAG TTC AAC-3ʹ
Rev: 5ʹ-CCC TAT GTG CTG GCC TTG AT-3ʹ
TaqMan: 5ʹ-CAC CAT GCA GAT TAT GCG GAT CAA ACC-3ʹ
72 NM001003175
VEGFR 1
For: 5ʹ-TGC CTG AAA CAG TGA GAA AGG A-3ʹ
Rev: 5ʹ-TGC AGA ACT GTT TGC CAT TCC-3ʹ
TaqMan: 5ʹ-AAA GGC TGA GCA TTA CTA AAT CTG CCT-3ʹ
81 AF262963
VEGFR 2
For: 5ʹ-TGA CAT GGC CTC GGT CAT T-3ʹ
Rev: 5ʹ-TGT TGG TCG CTA ACA GAA GCA-3ʹ
TaqMan: 5ʹ-CTA CGT TCA AGA TTA CAG GTC TCC ATT-3ʹ
75 DQ269018/NM001048024
EP 2
For: 5ʹ-CAC CCT GCT GCT GCT TCT C-3ʹ
Rev: 5ʹ -CGG TGC ATG CGG ATG AG-3ʹ
TaqMan: 5ʹ-TGC TCG CCT GCA ACT TTC AGC GTC-3ʹ
78 AF075602
EP 4
For: 5ʹ-AAA TCA GCA AAA ACC CAG ACT TG-3ʹ
Rev: 5ʹ-GCA CGG TCT TCC GCA GAA-3ʹ
TaqMan: 5ʹ-ATC CGA ATT GCT GCT GTG AAC CCT ATC C-3ʹ
96 AF177934
ERα
Forward: 5ʹ-CCC ATG GAG GAG ACA AAC CA-3ʹ
Reverse: 5ʹ-CCC TGC CTC GGT GAT ATA-3ʹ
TaqMan : 5ʹ-CAC GGG CCC AAC TTC ATC ACA TTC C-3ʹ
93 XM533454
ERβ
Forward: 5ʹ-CCC AGC CCC TTC A-3ʹ
Reverse: 5ʹ-AAT CAT ATG CAC GAG TTC CTT GTC-3ʹ
TaqMan : 5ʹ-CCT CCA TGA TGA TGT CCC TGA CC-3ʹ
78 XM861041
PRLR
Forward: 5ʹ-GGA TCT TTG CCG TTC TTT-3ʹ
Reverse: 5ʹ-AAG GAT GCA GGT CAC CAT GCT AT-3ʹ
TaqMan : 5ʹ-ATT ATG GTC GTA GCA GTG GCT TTG AAA GGC-3ʹ
92 HQ267784
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